Elections Reshape Congress But Not Supplement Industry Regulatory Outlook
This article was originally published in The Rose Sheet
Democrats potentially could target tightening regulatory oversight of some industries after regaining a majority in House, but Trump administration's high priority on reducing regulatory burdens bodes well that legislation to expand FDA's current authorities over the US supplement sector will not emerge before Congress' next session opens in 2021. NJ Democrat Frank Pallone could be member of Congress most commonly mentioned and lobbied by supplement industry during next session as Energy and Commerce chairman.
You may also be interested in...
“We would certainly want to have some enforcement and be able to utilize that enforcement,” says ODSP acting director Cara Welch. Stakeholders opposed to the change should “get comfortable with the idea of opening up DSHEA and should most certainly be part of the discussion.”
OTC drug and dietary supplement industries still emphasize lobbying for allowing direct purchases of their [products with pre-tax health savings accounts; streamlining FDA's process for adding OTC monograph ingredients and indications; and making multivitamins eligible for purchase with food stamps. They also remain vigilant about keeping Congress' hands off DSHEA, which reaches its 25th anniversary in October.
With a new US Congress just convening, OTC monograph reform advocates face an old problem: the need for Senate action. The House has already cleared an OTC reform measure, as part of a pandemic preparedness bill, in the first days of the legislative session.